Femasys (NASDAQ:FEMY) Research Coverage Started at Laidlaw

Laidlaw started coverage on shares of Femasys (NASDAQ:FEMY) in a research report report published on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $6.50 price objective on the stock.

A number of other research firms have also recently weighed in on FEMY. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Femasys in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Femasys to a “sell” rating in a research note on Saturday, October 4th. Finally, HC Wainwright dropped their price target on shares of Femasys from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Femasys currently has a consensus rating of “Moderate Buy” and an average price target of $6.83.

Femasys Trading Up 15.0%

Shares of Femasys stock opened at $0.92 on Thursday. Femasys has a 1-year low of $0.31 and a 1-year high of $1.80. The company’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $0.75. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.16 and a quick ratio of 0.41. The stock has a market capitalization of $53.80 million, a PE ratio of -1.28 and a beta of -2.55.

Femasys (NASDAQ:FEMY) last announced its earnings results on Friday, November 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Femasys had a negative return on equity of 764.26% and a negative net margin of 960.80%.The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.35 million. As a group, equities analysts anticipate that Femasys will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Femasys

Institutional investors and hedge funds have recently modified their holdings of the stock. Dauntless Investment Group LLC purchased a new position in shares of Femasys in the first quarter worth $1,969,000. Jane Street Group LLC purchased a new stake in Femasys in the 2nd quarter worth $82,000. Osaic Holdings Inc. bought a new position in shares of Femasys during the 2nd quarter valued at about $45,000. Finally, Clear Creek Financial Management LLC grew its position in shares of Femasys by 4.2% during the second quarter. Clear Creek Financial Management LLC now owns 281,821 shares of the company’s stock valued at $272,000 after purchasing an additional 11,450 shares in the last quarter. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.